Featured Research

from universities, journals, and other organizations

Trial Examines Diaphragm Use In Preventing HIV In Women

Date:
July 16, 2007
Source:
University of California - San Francisco
Summary:
A clinical trial involving 5,045 women in South Africa and Zimbabwe found no statistical difference in the rate of new HIV infections in the two study arms: those who received a diaphragm plus lubricant along with male condoms for their partners, and those who only received male condoms.

A clinical trial involving 5,045 women in South Africa and Zimbabwe found no statistical difference in the rate of new HIV infections in the two study arms: those who received a diaphragm plus lubricant along with male condoms for their partners and those who only received male condoms.

"In the context of a comprehensive HIV prevention package provided to all participants, the trial found no additional protective benefit against HIV infection from adding the diaphragm plus lubricant in the intervention arm," said the trial's lead investigator, Nancy Padian, PhD, director of UCSF's Women's Global Health Imperative.

The study, to be published online in The Lancet, reported an overall HIV incidence rate of 4.0 percent: 4.1 percent in the intervention arm that included provision of diaphragm and lubricant and 3.9 percent in the control arm that included only provision of condoms. Findings also showed 158 new HIV infections in the intervention arm and 151 in the control group.

"These results do not support the addition of the diaphragm to current HIV prevention strategies. Condoms remain the only proven barrier method for HIV prevention," said Padian.

All participants in the trial received a comprehensive package of safer-sex and family planning counseling, free male condoms, diagnosis and treatment of curable sexually transmitted infections, and free contraception.

The investigators could not evaluate whether using the diaphragm alone was better than using nothing, because most women in both arms of the trial reported male condom use.

The trial, known at "Methods for Improving Reproductive Health in Africa, or MIRA, began in 2003 and was conducted at sites in Harare, Zimbabwe, and Soweto and Durban, South Africa. The trial was launched because previous data has suggested that the cells in the cervix are particularly vulnerable to HIV infection, and use of a diaphragm presented the potential for protection. A flexible, dome-shaped rubber disk, a diaphragm is inserted vaginally with a gel to cover the cervix.

Collaborating institutions included the University of Zimbabwe-University of California, San Francisco Collaborative Research Program; Medical Research Council, HIV Prevention Research Unit of the (Durban); Perinatal HIV Research Unit, University of the Witwatersrand; and Ibis Reproductive Health.

The study was funded by the Bill & Melinda Gates Foundation.


Story Source:

The above story is based on materials provided by University of California - San Francisco. Note: Materials may be edited for content and length.


Cite This Page:

University of California - San Francisco. "Trial Examines Diaphragm Use In Preventing HIV In Women." ScienceDaily. ScienceDaily, 16 July 2007. <www.sciencedaily.com/releases/2007/07/070713233423.htm>.
University of California - San Francisco. (2007, July 16). Trial Examines Diaphragm Use In Preventing HIV In Women. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2007/07/070713233423.htm
University of California - San Francisco. "Trial Examines Diaphragm Use In Preventing HIV In Women." ScienceDaily. www.sciencedaily.com/releases/2007/07/070713233423.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins